OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
February 02, 2024
Allarity reached an agreement with Novartis in 2018 to license dovitinib, a small molecule multi-tyrosine kinase inhibitor under evaluation for the treatment of renal cell carcinoma.
Treatment with the novel engineered T-cell receptor produced an overall response rate of about 39% in patients with heavily pretreated synovial sarcoma.
Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
BST02 is a novel cell-based immunotherapy currently being evaluated in a Phase I trial for the treatment of all types of liver cancer.
February 01, 2024
Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.
In order to provide both profitability and medication access, a balancing act is required.
Duplicate rebates have resulted in revenue leakage for manufacturers.
DELFI-TF assay shows promise in evaluating treatment response and resistance to immunotherapies in patients with advanced cancers.
Rusfertide could potentially be a first-in-class, transformational treatment for polycythemia vera.
Vabysmo, the first bispecific antibody approved by the FDA for ocular conditions, produced significant drying of retinal fluid, which is often associated with blurry vision.